Tag Archives: Novartis

Novartis’ new cell therapy facility could ease manufacturing squeeze for CAR-T med Kymriah

Novartis’ big push into cell and gene therapy hasn’t been the smoothest of rides, with a data manipulation scandal hamstringing Zolgensma and manufacturing concerns hurting CAR-T cancer therapy Kymriah. Could a new European facility help turn around the latter’s production bottleneck?  Novartis last week opened its newest cell and gene therapy facility in Stein, Switzerland,… Read More »

Novartis has its blockbuster Beovu OK, but its ‘hot mess’ label leaves something to be desired: analysts

Novartis has big plans for its new wet age-related macular degeneration drug Beovu, but as some doctors and analysts see it, the company has an uphill climb thanks to uncertainties and shortcomings in the med’s label.  After holding a call with a key opinion leader, SVB Leerink analyst Geoffrey Porges wrote that the “lack of clarity” about Beovu’s dosing schedule will serve as one… Read More »

Lilly tees up another Novartis battle with ankylosing spondylitis OK for Taltz

Eli Lilly’s Taltz is cruising toward blockbuster territory, and now it has a new indication to help it get there. Monday, the FDA green-lighted the drug in ankylosing spondylitis (AS), adding to the go-aheads it received in December 2017 for psoriatic arthritis (PsA) and in March 2016 for plaque psoriasis. With the new launch, Lilly… Read More »

Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve

Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer. The Swiss drugmaker will roll out the drug, a one-time treatment for pediatric patients less than 2 years of… Read More »

Commentary: Novartis CEO: Gene therapy offers hope of cures in a treatment, but US needs new pricing, payment model

We live in an incredible era of progress in human health. Advances in cell and gene therapies are beginning to yield powerful new treatments for some of the most devastating illnesses. With many of these new therapies we are no longer combating diseases over time, but potentially curing them in a single treatment. This is… Read More »